Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award (https://www.cmoleadershipawards.com/) across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). Hovione was given additional recognition as a CDMO Leadership Award Champion in the categories of Compatibility and Expertise for scoring as a top performer in comparison to the weighted average of other CDMOs included in the Industry Standard Research (ISR)’s annual Contract Manufacturing Quality Benchmarking survey.
Established in 2011 by Outsourced Pharma and Life Science Leader, the CDMO Leadership Awards spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The CDMO Leadership Awards teamed up with ISR to determine the award recipients – 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.
“We are honored and proud to receive this award in all six categories. This broad recognition reflects the dedication of our team to help our customers deliver much-needed medicines to the market,” said Dr. Jean-Luc Herbeaux, Hovione’s CEO. “This is not the first time Hovione is recognized by the CDMO Leadership awards and winning these awards once again reinforces our commitment to excellence and differentiation in the services we provide to our customers.”
“For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma.
Hovione has been expanding (https://www.hovione.com/press-room/press-release/hovione-invests-170-million-new-capacity-and-capabilities) worldwide, demonstrating the commitment to its customers. Hovione has been investing in new laboratory and production assets and innovative technologies (https://www.hovione.com/press-room/press-release/hovione-expands-drug-product-offering-new-manufacturing-line-dedicated-continuous-tableting) to meet customer demand for integrated and differentiated services in manufacturing of drug substances, particles and drug products.
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) (https://go.hovione.com/e/47122/ontract-manufacturing-services/8wjzq5/2436741121?h=xIUzj2eUnalGXhlPJn3XyuRuixnG8bdX6YCeda_Eqg8) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites (https://go.hovione.com/e/47122/hovione-worldwide/8wjzq8/2436741121?h=xIUzj2eUnalGXhlPJn3XyuRuixnG8bdX6YCeda_Eqg8) in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture (https://go.hovione.com/e/47122/-services-particle-engineering/8wjzqc/2436741121?h=xIUzj2eUnalGXhlPJn3XyuRuixnG8bdX6YCeda_Eqg8) of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione´s culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
For more information, please visit www.hovione.com (http://www.hovione.com/) or contact:
Vanessa Romeu | Communications Director | firstname.lastname@example.org |Tel: +351 21 982 9000